English press releases

IFF Declares Dividend for Fourth Quarter 2020

NEW YORK–(BUSINESS WIRE)– IFF (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of scent, taste, and nutrition, announced that its Board of Directors...

FOCUS Study Shows MammaPrint® Accurately Identifies Extremely Indolent Cancers

 Findings confirm subanalysis of STO-3 trial and provide foundation for consideration of de-escalation of treatment in post-menopausal patients guided by genomic testing IRVINE, Calif., &...

Agendia Presents Broad Spectrum of Data from FLEX Study Highlighting Tumor Heterogeneity within Underrepresented or Underserved Patient Populations at SABCS 2020

Agendia shares subgroup analyses from the first of its kind, national FLEX Registry with complete, clinically-annotated full genome expression profiling IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)–...

EAG Laboratories Announces Latest Advancement in Transmission Electron Microscopy

SUNNYVALE, Calif.–(BUSINESS WIRE)– EAG Laboratories is pleased to announce the completed installation of a ThermoFisher Scientific Themis Z Transmission Electron Microscope (TEM) at our Silicon...

Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program

Boehringer Ingelheim has signed the agreement on the acquisition of all shares of Germany-based biotech company Labor Dr. Merk & Kollegen Transaction expands Boehringer Ingelheim’s...

ADVA and Advantech simplify remote uCPE rollout with the launch of a virtual lab

News summary: CSP engineers working remotely to evaluate SD-WAN, security and enterprise edge solutions face logistical challenges ADVA and Advantech’s test-drive portal offers virtual test...

Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema

− TAKHZYRO is the first approved modern therapy for the preventive treatment of hereditary angioedema (HAE) in patients 12 years and older in China1 −...

P.I. Works Joins the O-RAN ALLIANCE to Drive Open Radio Access Network Innovations

P.I. Works joins forces with the O-RAN ALLIANCE to contribute to the transformation of radio access networks towards open, intelligent, virtualized and fully interoperable architecture....

Seoul Viosys’ Violeds Technology for Escalator Handrail Sterilization Solutions

ANSAN, South Korea–(BUSINESS WIRE)– Seoul Viosys (KOSDAQ: 092190), a leading compound semiconductor solution provider, announced that ‘Violeds’ technology has been applied to an escalator handrail...

IFF Receives All Required Antitrust Clearances for Intended Combination with DuPont’s Nutrition & Biosciences Business

Transaction Remains on Track to Close in First Quarter of 2021 NEW YORK & WILMINGTON, Del.–(BUSINESS WIRE)– Regulatory News: IFF (NYSE: IFF) (Euronext Paris: IFF)...

Philip Morris International Announces U.S. Food and Drug Administration Authorization of IQOS 3 for Sale in the United States

NEW YORK–(BUSINESS WIRE)– The U.S. Food and Drug Administration (FDA) today confirmed that IQOS 3, Philip Morris International’s electrically heated tobacco system, is appropriate for...

Elliott Statement on ARYZTA

LONDON–(BUSINESS WIRE)– Elliott Advisors (UK) Limited (“Elliott” or “we”) notes speculation in the market regarding a media release ARYZTA AG (“ARYZTA”) has published this morning....

Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders – a Novel Approach to Fight Cancer

– New collaboration strengthens Boehringer Ingelheim’s cancer research strategy to develop novel treatment options for patients with lung or gastrointestinal cancers – Proxygen’s unique molecular...

Rhizen Pharmaceuticals SA Announces Presentation of the Interim Results of the Phase I/II study of Tenalisib (RP6530) in Combination with Romidepsin in Relapsed/Refractory T-cell Lymphoma at American Society of Hematology (ASH) annual meeting, 2020

Rhizen announces presentation of interim data from its Tenalisib + Romidepsin combination study in patients with relapsed/refractory peripheral and cutaneous T cell lymphoma. The Tenalisib...

New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint

− Primary endpoint defined as the proportion of patients who achieved confirmed CMV viremia clearance at the end of Study Week 8 OSAKA, Japan–(BUSINESS WIRE)–...